Skip to content

Acotiamide Oral Therapy in Acute Phase for Postgastrectomy Syndrome

Acotiamide Oral Therapy in Acute Phase for Postgastrectomy Syndrome - Acotiamide Oral Therapy in Acute Phase for Postgastrectomy Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024466
Enrollment
35
Registered
2016-10-25
Start date
2016-10-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postgastrectomy Syndrome

Interventions

Orally intake acotiamide(100mg) three times a day for 8 weeks starting from 4-7 days post operation.

Sponsors

Nagasaki University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age: Age over 20 years old and below 85 years old at the time of consent 2.Sex: Male and Female 3.In-patient/Out-patient: Either 4.Patients who have undergone gastrectomy and gasric-reconstruction and have started food intake within 3 to 7 days post operation. 5.Patients who consent and sign with complete understanding of the study after adequate explanation as to the particulars of the study, or patients whose guardian consents to their participation in the study.

Exclusion criteria

Exclusion criteria: 1.Cases where gastrectomy was not radical operation (Peritoneal dissemination etc.) 2.Cases with enterostomy 3.Cases with total gastrectomy 4.Patients with medication sensitivity 5.Patients during pregnancy and lactation. 6.Patients who test responsibility (sharing) doctor has determined to be inappropriate as a subject.

Design outcomes

Primary

MeasureTime frame
Evaluating symptom diaries utilizing Roma III standards categories (On weeks 1,2,3,4,8)

Secondary

MeasureTime frame
Achieving over 70% of the pre-operational food intake (On weeks 2,4,8). Intra-abdominal fat evaluation and evaluation for atrophy rate of psoas major by CT-scan on the 8 week post surgery. Nutritional index evaluation (prealbumin,retinol-binding protein,albumin,GLP-1), SF-NDI scale,F-scale (On weeks 0,4,8).

Countries

Japan

Contacts

Public ContactShinichiro Kobayashi

Nagasaki University Graduate School of Biomedical Sciences Surgery

shinichirokobayashi@nagasaki-u.ac.jp0958197316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026